白血病·淋巴瘤
白血病·淋巴瘤
백혈병·림파류
JOURNAL OF LEUKEMIA & LYMPHOMA
2013年
10期
597-599
,共3页
张津京%王萍萍%曲艺%李艳
張津京%王萍萍%麯藝%李豔
장진경%왕평평%곡예%리염
白血病,髓细胞,急性%免疫分型%流式细胞术
白血病,髓細胞,急性%免疫分型%流式細胞術
백혈병,수세포,급성%면역분형%류식세포술
Leukemia,myeloid,acute%Immunophenotyping%Flow cytometry
目的 探讨急性髓系白血病(AML)的免疫表型特点及其与疗效的关系.方法 采用流式细胞术(FCM)对96例初诊的AML患者进行免疫表型检测.结果 96例AML患者髓系抗原表达依次为CD13 97.92％(94/96),CD11789.58％(86/96),CD33 82.29％(79/96).干/祖细胞分化抗原表达依次为CD38 95.83％(92/96),HLA-DR 75.00％(72/96),CD34 62.5％(60/96).而M3极少表达CD34及HLA-DR.CD14只在M4及M5中表达.淋系抗原在AML患者中也有阳性表达,其中CD4 37.5％(36/96),CD722.92％(22/96),CD2 10.42％(10/96).对其中46例患者进行疗效分析,总完全缓解(CR)率为67.39％(31/46).CD33、CD1t7、CD1tb、CD14、CD64、CD4、CD34、HLA-DR等抗原表达阳性组与阴性组间CR率差异无统计学意义(确切概率法,均P＞0.05).但CD7阳性患者CR率明显低于阴性者,差异有统计学意义(确切概率法,P＜0.05).结论 CD33、CD17、CD117是AML最常见的免疫标志3伴CD7阳性表达的AML患者对化疗反应差.
目的 探討急性髓繫白血病(AML)的免疫錶型特點及其與療效的關繫.方法 採用流式細胞術(FCM)對96例初診的AML患者進行免疫錶型檢測.結果 96例AML患者髓繫抗原錶達依次為CD13 97.92％(94/96),CD11789.58％(86/96),CD33 82.29％(79/96).榦/祖細胞分化抗原錶達依次為CD38 95.83％(92/96),HLA-DR 75.00％(72/96),CD34 62.5％(60/96).而M3極少錶達CD34及HLA-DR.CD14隻在M4及M5中錶達.淋繫抗原在AML患者中也有暘性錶達,其中CD4 37.5％(36/96),CD722.92％(22/96),CD2 10.42％(10/96).對其中46例患者進行療效分析,總完全緩解(CR)率為67.39％(31/46).CD33、CD1t7、CD1tb、CD14、CD64、CD4、CD34、HLA-DR等抗原錶達暘性組與陰性組間CR率差異無統計學意義(確切概率法,均P＞0.05).但CD7暘性患者CR率明顯低于陰性者,差異有統計學意義(確切概率法,P＜0.05).結論 CD33、CD17、CD117是AML最常見的免疫標誌3伴CD7暘性錶達的AML患者對化療反應差.
목적 탐토급성수계백혈병(AML)적면역표형특점급기여료효적관계.방법 채용류식세포술(FCM)대96례초진적AML환자진행면역표형검측.결과 96례AML환자수계항원표체의차위CD13 97.92％(94/96),CD11789.58％(86/96),CD33 82.29％(79/96).간/조세포분화항원표체의차위CD38 95.83％(92/96),HLA-DR 75.00％(72/96),CD34 62.5％(60/96).이M3겁소표체CD34급HLA-DR.CD14지재M4급M5중표체.림계항원재AML환자중야유양성표체,기중CD4 37.5％(36/96),CD722.92％(22/96),CD2 10.42％(10/96).대기중46례환자진행료효분석,총완전완해(CR)솔위67.39％(31/46).CD33、CD1t7、CD1tb、CD14、CD64、CD4、CD34、HLA-DR등항원표체양성조여음성조간CR솔차이무통계학의의(학절개솔법,균P＞0.05).단CD7양성환자CR솔명현저우음성자,차이유통계학의의(학절개솔법,P＜0.05).결론 CD33、CD17、CD117시AML최상견적면역표지3반CD7양성표체적AML환자대화료반응차.
Objective To investigate the immunophenotypic characteristics of acute myeloid leukemia (AML)and its relationship with chemotherapy response.Methods The immunophenotyping was performrd by flow cytometry in 96 newly diagnosed AML patients.Results In 96 patients with AML,the myeloid antigens were mainly expressed including CD13(94/96,97.92％),CD117(86/96,89.58％),CD33(79/96,82.29％)respectively.The positive expression of stem/progenitor cell differentiation antigens were CD38 (92/96,95.83％),HLA-DR(72/96,75.00％)and CD34(60/96,62.50％).While CD34 and HLA-DR were fewly expressed in M3.The CD14 was only expressed in M4 and M5.The lymphocytic antigens had positive expression in the patients with AML,in which CD4 was 37.5％(36/96),CD7 was 22.92％(22/96)and CD2 was 10.42 ％(10/96).In 46 patients for treatment response analysis,total CR rate was 67.39％(31 /46).There was no significant difference of CR rates between the antigens positive group and negative group including CD33,CD117,CD11b,CD14,CD64,CD4,CD34 and HLA-DR.However,the CR rate was significantly lower in CD7 positive cases than CD7 negative ones,with statistically significance difference(P=0.01).Conclusions CD13,CD33and CD117 are the most common antigens in AML.The patients with the positive expression of CD7 have poor response to chemotherapy in AML.
